The importance of pharmacoepidemiology in pregnancy-implications for safety

被引:23
作者
Benevent, Justine [1 ]
Montastruc, Francois [1 ]
Damase-Michel, Christine [1 ]
机构
[1] Univ Toulouse III, Fac Med, CRPV Midi Pyrenees, CHU Toulouse,UMR INSERM 1027,CIC 1436, Toulouse, France
关键词
Electronic database; medication; pharmacoepidemiology; pregnancy; teratogen; TERATOLOGY INFORMATION-SERVICES; IN-UTERO EXPOSURE; CONGENITAL-MALFORMATIONS; DRUG; RISK; PRESCRIPTION; EFEMERIS; COHORT; DATABASE; DEFECTS;
D O I
10.1080/14740338.2017.1363177
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Prescription of medications to pregnant women is usually a challenge as the drug benefit has to be considered regarding its potential adverse effects. As medication use is common in pregnant women, by chance or necessity, it gives the opportunity to evaluate the consequences of prenatal drug exposure in real life through pharmacoepidemiologic studies. Area covered: Data sources are numerous. Some of them have been created for the particular purpose of assessing medications during pregnancy. Augmented databases enable the study of delayed effects in late childhood and provide information on potential confounders. Each data source exhibits strengths and weaknesses. Several designs can be used to assess the safety of medications during pregnancy. Innovative designs have been developed in order to bypass major limits of classical methods. Expert opinion: An efficient system could follow up each pregnant woman, who had taken a medication, and consider her as a precious information for the knowledge of drug potential adverse actions against the child, who must be followed up to identify long term-effects. The diversity of data sources and approaches of pharmacoepidemiologic studies, the implementation of international networks as well as the improvement of adverse signal detection are the keystones of such an evaluation.
引用
收藏
页码:1181 / 1190
页数:10
相关论文
共 54 条
  • [11] 50 years of the Hungarian Congenital Abnormality Registry
    Czeizel, Andrew E.
    Metneki, Julia
    Beres, Judit
    [J]. CONGENITAL ANOMALIES, 2014, 54 (01) : 22 - 29
  • [12] Damase-Michel C., 2000, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V29, P77
  • [13] Drug counselling in pregnancy:: community pharmacists
    Damase-Michel, C
    Vié, C
    Lacroix, I
    Lapeyre-Mestre, M
    Montastruc, JL
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (10) : 711 - 715
  • [14] Drug in Pregnancy: Studies in the French Database EFEMERIS
    Damase-Michel, Christine
    Lacroix, Isabelle
    Hurault-Delarue, Caroline
    Beau, Anna-Belle
    Montastruc, Jean-Louis
    [J]. THERAPIE, 2014, 69 (01): : 91 - 100
  • [15] Damase-Michel Christine, 2008, Pharmacy Pract (Granada), V6, P15
  • [16] Inequalities in perinatal and maternal health
    de Graaf, Johanna P.
    Steegers, Eric A. P.
    Bonsel, Gouke J.
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2013, 25 (02) : 98 - 108
  • [17] Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study
    de Jonge, Linda
    Garne, Ester
    Gini, Rosa
    Jordan, Susan E.
    Klungsoyr, Kari
    Loane, Maria
    Neville, Amanda J.
    Pierini, Anna
    Puccini, Aurora
    Thayer, Daniel S.
    Tucker, David
    Hansen, Anne Vinkel
    Bakker, Marian K.
    [J]. DRUG SAFETY, 2015, 38 (11) : 1083 - 1093
  • [18] Risk of drug-induced congenital defects
    De Santis, M
    Straface, G
    Carducci, B
    Cavaliere, AF
    De Santis, L
    Lucchese, A
    Merola, AM
    Caruso, A
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2004, 117 (01) : 10 - 19
  • [19] Centre de reference stir les agents teratogenes (CRAT): a pioneer center
    Elefant, Elisabeth
    Vauzelle, Catherine
    Beghin, Delphine
    [J]. THERAPIE, 2014, 69 (01): : 39 - 45
  • [20] European Medicines Agency-Pharmacovigilance-Good pharma-covigilance practices [Internet], PHARM GOOD PHARMC PR